Clinical utility and validity of minoxidil response testing in androgenetic alopecia. Issue 1 (12th August 2014)

• Record Type: Journal Article
• Authors: Goren, Andy; Shapiro, Jerry; Roberts, Janet; McCoy, John; Desai, Nisha; Zarrab, Zoulikha; Pietrzak, Aldona; Lotti, Torello
• Is Part Of: Dermatologic therapy. Volume 28:Issue 1(2015)
• Page Start: 13
• Page End: 16
• Publication Date: 2014-08-12
• Subjects: Skin -- Diseases -- Periodicals; Dermatology -- Periodicals; 616.5
• DOI: 10.1111/dth.12164
• Languages: English
• ISSNs: 1396-0296

Abstract

<abstract abstract-type="main"> <title>Abstract</title> <p>Clinical response to 5% topical minoxidil for the treatment of androgenetic alopecia (AGA) is typically observed after 3–6 months. Approximately 40% of patients will regrow hair. Given the prolonged treatment time required to elicit a response, a diagnostic test for ruling out nonresponders would have significant clinical utility. Two studies have previously reported that sulfotransferase enzyme activity in plucked hair follicles predicts a patient's response to topical minoxidil therapy. The aim of this study was to assess the clinical utility and validity of minoxidil response testing. In this communication, the present authors conducted an analysis of completed and ongoing studies of minoxidil response testing. The analysis confirmed the clinical utility of a sulfotransferase enzyme test in successfully ruling out 95.9% of nonresponders to topical minoxidil for the treatment of AGA.</p> </abstract>